Markkanen-Leppänen Mari, Mäkitie Antti A, Passador-Santos Fabricio, Leivo Ilmo, Hagström Jaana
Department of Otolaryngology and Head and Neck Surgery, Helsinki University Central Hospital, and Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Clin Med Insights Pathol. 2010 Feb 18;3:1-5. doi: 10.4137/cpath.s3303.
We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy. BcAC is a salivary gland malignancy first recognized as a distinct neoplastic entity in WHO classification of salivary gland tumours in 1991. Over 90% of BcACs are detected in the parotid gland. The most important differential diagnosis is basal cell adenoma. Infiltrative growth is the distinguishing feature of BcAC. Administration of immunosuppressive medication to this patient for three decades may have contributed to development of this rare neoplasia. To our knowledge, similar cases of BcAC have not been reported previously.
我们报告了一例罕见的腮腺双侧基底细胞腺癌（BcAC）病例，该患者为男性，肾移植术后30年并持续接受免疫抑制治疗。BcAC是一种唾液腺恶性肿瘤，于1991年在世界卫生组织唾液腺肿瘤分类中首次被确认为一种独特的肿瘤实体。超过90%的BcAC发生于腮腺。最重要的鉴别诊断是基底细胞腺瘤。浸润性生长是BcAC的显著特征。该患者接受免疫抑制药物治疗三十年可能促成了这种罕见肿瘤的发生。据我们所知，此前尚未有类似的BcAC病例报道。
